Skip to main content

Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal

European Journal of Drug Metabolism and Pharmacokinetics volume 22, pages 103–110 (1997)Cite this article

Summary

The effect of a high-fat meal on the pharmacokinetics of mirtazapine was studied in 19 healthy normal young male volunteers. In a randomized two-period crossover study, each volunteer received an oral dose of 15 mg of mirtazapine in the form of tablets, in the fasting state and after a high-fat meal, with a washout period of 14 days between the two doses. Serial blood samples were taken and pharmacokinetic parameters calculated and statistically analyzed from mirtazapine plasma levels.

The extent of absorption of mirtazapine, as measured by the area under the plasma level versus time curve, was found to be equivalent for the fasting and the fed state. Food intake was shown to have no influence on the elimination of mirtazapine, as measured by its elimination half-life.

The rate of mirtazapine absorption, as measured by the peak level (Cmax), was not altered by food. The peak time (tmax), however, in subjects in the fed state showed an increase: the 90%-confidence interval for the median difference ranged from 0.25 to 1.25 h. This was the only effect of food found in this study. It is considered to be of no clinical consequence.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. De Boer T., Nefkens F., Van Helvoirt A. (1994): The α2 antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol., 253, R5-R6.

    Article  PubMed  Google Scholar 

  2. De Boer T., Ruigt G.S.F. (1995): The selective α2-adrenoreceptor antagonist Org 3770 (mirtazapine) enhances noradrenergic and serotonin1A-mediated serotonergic neurotransmission. CNS Drugs, 4 (Suppl 1), 29–38.

    Article  Google Scholar 

  3. De Montigny C., Haddjeri N., Mongeau R., Blier P. (1995): The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs, 4 (Suppl 1), 13–17.

    Article  Google Scholar 

  4. De Boer T., Maura G., Raiteri M., De Vos C.J., Wieringa J., Pinder R.M. (1988): Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of minaserin, Org 3770 and its enantiomers. Neuropharmacology, 27, 399–408.

    Article  PubMed  Google Scholar 

  5. Bremner J.D. (1995): A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J. Clin. Psychiatry, 56, 519–525.

    PubMed  CAS  Google Scholar 

  6. Claghorn J.L., Lessem M.D. (1995): A double-llind placebo controlled study of Org 3770 in depressed outpatients. J. Affect. Disord., 34, 165–171.

    Article  PubMed  CAS  Google Scholar 

  7. Sitsen J.M.A., Zivkov M., Dieterle D. (1995): Wirksamkeit und Verträglichkeit von Org 3770 bei Patienten mit einer Major Depression. Psychopharmakotherapie, 2, 68–71.

    Google Scholar 

  8. Kahn M.C. (1995): A randomised, double-blind, placebo-controlled, 5-weeks’ study of Org 3770 (mirtazapine) in major depression. Hum. Psychopharmacol., 10, (Suppl 2), S119-S124.

    Article  Google Scholar 

  9. Van Moffaert M., De Wilde J., Vereecken A. et al. (1995): Mirtazapine is more effective than trazodone. A controlled study in hospitalised patients with major depression. Int. Clin. Psychopharmacol., 10, 3–9.

    Article  PubMed  Google Scholar 

  10. Mullin J., Lodge A., Bennie E., McCreadie R., Bhatt G.S., Fenton G. (1997): A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J. Psychopharmacol., In press.

  11. Zivkov M., De Jongh G. (1995): Org 3770 vs amitriptyline; a 6-week, randomised double-blind multicentre trial in hospitalised patients. Hum. Psychopharmacol., 10, 263–271.

    Article  Google Scholar 

  12. Richou H., Ruimy P., Charbaut J. et al. (1995): A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol., 10, 263–271.

    Article  CAS  Google Scholar 

  13. Marttilla M., Jääskeläinen J., Järvi R. et al. (1995): A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur. Neuropsychopharmacol., 5, 441–446.

    Article  Google Scholar 

  14. Zivkov M., Roes K.C.B., Pols A.G. (1995): Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum. Psychopharmacol., 10 (Suppl 2), S135-S145.

    Article  CAS  Google Scholar 

  15. Halikas J.A. (1995): Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum. Psychopharmacol., 10 (Suppl 2), S125-S133.

    Article  CAS  Google Scholar 

  16. Hoyberg O.J., Maragakis B., Mullin J. et al. (1997). A double blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr. Scand., In press.

  17. Voortman G., Paanakker J.E. (1995): Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum. Psychopharmacol., 10 (Suppl 2), S83-S96.

    Article  CAS  Google Scholar 

  18. Timmer C.J., Lohmann A., Mink C.P.A. (1995): Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum. Psychopharmacol., 10, (Suppl 2), S97-S106.

    Article  CAS  Google Scholar 

  19. Timmer C.J., Paanakker J.E., Van Hal H.J.M. (1996): Pharmacokinetics of mirtazapine from orally administered tablets; influence of gender, age and treatment regimen. Hum. Psychopharmacol., In press.

  20. Kaspersen F.M., Van Rooij A.A.M., Sperling E.G.M., Wieringa J.H. (1989): The synthesis of Org 3770 labelled with3H,13C and14C. J. Labelled Compounds Radiopharmaceut., 27, 1055–1068.

    Article  CAS  Google Scholar 

  21. Paanakker J.E., Van Hal H.J.M. (1987): Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J. Chromatogr. Biomed. Appl., 417, 203–207.

    Article  CAS  Google Scholar 

  22. SAS Institute Inc., (1989): SAS User’s Guide, Version 6.06. Cary, NC, USA: SAS Institute Inc.

    Google Scholar 

  23. US Food and Drug Administration Guidance (1992): Statistical procedures for bioequivalence testing using a standard two-treatment cross-over design. Statement prepared by the Division of Bioequivalence, Office of Generic Drugs of the FDA, informal communication under 21 CFR 10.90.

  24. Commission on the European Communities, Committee for Proprietary Medicinal Products CPMP. Note for Guidance, Investigation of Bioavailability and Bioequivalence, III/54/89-EN.

  25. Wijnand H.P. (1993): Bioequivalence revisited — non-parametric analysis of two-period cross-over studies. Computer Methods Progr. Biomed., 49, 249–259.

    Article  Google Scholar 

  26. Schuirmann D.J. (1987): A comparison of the two one-sided tests procedure and the power approach for testing equivalence in bioequivalence assessment. J. Pharmacokinet. Biopharm., 15, 657–680.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Organon Inc, West Orange, New Jersey, USA

    M. Cohen & J. Panagides

  2. Department of Drug Metabolism and Kinetics, NV Organon, PO Box 20, 5340 BA, Oss, The Netherlands

    C. J. Timmer & J. A. M. Huisman

Authors
  1. M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Panagides
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. J. Timmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. A. M. Huisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cohen, M., Panagides, J., Timmer, C.J. et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. European Journal of Drug Metabolism and Pharmacokinetics 22, 103–110 (1997). https://doi.org/10.1007/BF03189792

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189792

Keywords

  • Remeron
  • mirtazapine
  • Org 3770
  • antidepressant
  • pharmacokinetics